Advances in Newly Diagnosed Multiple Myeloma: The Impact of More Intensive Therapy on Clinical Outcomes

Experts discuss therapeutic advances for newly diagnosed multiple myeloma and elaborate on the impact and availability of more intensive therapies on clinical outcomes.

Share

Program Content

Activities

CD38 in MM
Rationale for Targeting CD38, Disparities in Care, and Treatment Implications in Newly Diagnosed MM
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 10, 2024

Expires: June 09, 2025

Quad Tx in ASCT Eligible NDMM
The Impact of Quadruplet Therapy Incorporating CD38 Antibodies in Transplant-Eligible Patients With NDMM
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 11, 2024

Expires: June 10, 2025

CD38 mAb in ASCT Ineligible NDMM
Optimizing Clinical Outcomes With CD38 Antibodies for Transplant-Ineligible Patients With NDMM
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 11, 2024

Expires: June 10, 2025

Activities

NDMM at EHA 2024
Experts Discuss Advances in Newly Diagnosed Multiple Myeloma: The Impact of More Intensive Therapy on Clinical Outcomes
Video
Congratulations: You achieved a completion on 04/09/2022

Released: September 17, 2024

Expires: September 16, 2025

Activities

Newly Diagnosed Myeloma
Key Questions in the Management of Newly Diagnosed Multiple Myeloma
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: August 14, 2024

Expires: August 13, 2025

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC

Supporters

Supported by an educational grant from Sanofi.

Sanofi